JP2017506640A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506640A5
JP2017506640A5 JP2016551824A JP2016551824A JP2017506640A5 JP 2017506640 A5 JP2017506640 A5 JP 2017506640A5 JP 2016551824 A JP2016551824 A JP 2016551824A JP 2016551824 A JP2016551824 A JP 2016551824A JP 2017506640 A5 JP2017506640 A5 JP 2017506640A5
Authority
JP
Japan
Prior art keywords
edc
alkyl
present
targeting moiety
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551824A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506640A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/016212 external-priority patent/WO2015123687A1/en
Publication of JP2017506640A publication Critical patent/JP2017506640A/ja
Publication of JP2017506640A5 publication Critical patent/JP2017506640A5/ja
Pending legal-status Critical Current

Links

JP2016551824A 2014-02-14 2015-02-17 細胞外標的化薬物共役体 Pending JP2017506640A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461940219P 2014-02-14 2014-02-14
US61/940,219 2014-02-14
US201461946314P 2014-02-28 2014-02-28
US61/946,314 2014-02-28
PCT/US2015/016212 WO2015123687A1 (en) 2014-02-14 2015-02-17 Extracellular targeted drug conjugates

Publications (2)

Publication Number Publication Date
JP2017506640A JP2017506640A (ja) 2017-03-09
JP2017506640A5 true JP2017506640A5 (enExample) 2018-03-08

Family

ID=53800709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551824A Pending JP2017506640A (ja) 2014-02-14 2015-02-17 細胞外標的化薬物共役体

Country Status (4)

Country Link
US (2) US10675352B2 (enExample)
EP (1) EP3104882B1 (enExample)
JP (1) JP2017506640A (enExample)
WO (1) WO2015123687A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190008983A1 (en) 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
US11351254B2 (en) * 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3635001A1 (en) 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
AU2018280871B2 (en) 2017-06-08 2024-09-26 Black Belt Therapeutics Ltd CD38 modulating antibody
EP4509143A3 (en) * 2017-06-20 2025-04-23 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
BR112021009750A2 (pt) 2018-12-20 2021-08-17 Kleo Pharmaceuticals, Inc terapia de combinação de arms e células exterminadoras naturais
WO2021003050A2 (en) * 2019-07-03 2021-01-07 Kleo Pharmaceuticals, Inc. Cd38-binding agents and uses thereof
CN118420744A (zh) 2019-12-30 2024-08-02 甘李药业股份有限公司 胰岛素衍生物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4364935A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE69638269D1 (de) 1995-06-14 2010-11-18 Univ California Hochaffine humane antikörper gegen tumorantigene
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2385743A1 (en) 1999-09-28 2001-04-05 Universitat Zurich Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン,エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20080111066A1 (en) * 2005-08-31 2008-05-15 Jing Jim Zhang Derivatization and low level detection of drugs in biological fluid and other solution matrices using a proxy marker
US20090285780A1 (en) 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101520150A (zh) 2008-04-08 2009-09-02 王跃农 一种方便型节能吸顶灯
US20100017480A1 (en) 2008-07-17 2010-01-21 International Business Machines Corporation Recipient side grouping of addresses
US20120122514A1 (en) 2008-10-23 2012-05-17 Qualcomm Incorporated Selecting network service providers for multi-mode mobile devices
US8367419B2 (en) 2009-06-25 2013-02-05 Rutgers, The State University Of New Jersey Compositions and methods for detection of explosives
JP2013504585A (ja) * 2009-09-09 2013-02-07 セントローズ, エルエルシー 細胞外標的化薬物複合体
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
NZ607473A (en) * 2010-09-27 2014-11-28 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
WO2012050884A2 (en) 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
WO2012075337A2 (en) * 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CN107080847A (zh) * 2011-06-24 2017-08-22 森彻斯有限公司 细胞外靶向药物缀合物
AU2012348017A1 (en) 2011-12-05 2014-07-03 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
US20190008983A1 (en) * 2015-07-31 2019-01-10 James R. Prudent Extracellular drug conjugates targeting cd20
US20170049908A1 (en) * 2015-08-17 2017-02-23 Centrose, Llc Extracellular targeted drug conjugates

Similar Documents

Publication Publication Date Title
JP2011500725A5 (enExample)
JP2016516068A5 (enExample)
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
JP2014521688A5 (enExample)
JP2016508130A5 (enExample)
JP2015534578A5 (enExample)
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
JP2019513764A5 (enExample)
JP2015527318A5 (enExample)
WO2012107706A8 (en) Phenothiazine diaminium salts and their use
JP2016513696A5 (enExample)
JP2016516043A5 (enExample)
JP2014500295A5 (enExample)
JP2016515561A5 (enExample)
JP2015527319A5 (enExample)
MX2021011811A (es) Protacs que degradan el receptor de estrogeno.
JP2016515628A5 (enExample)
WO2009082818A8 (en) Novel c-21-keto lupane derivatives preparation and use thereof
JP2012505838A5 (enExample)
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
JP2016522179A5 (enExample)
CA2896976A1 (en) Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
JP2017503014A5 (enExample)
JP2019533651A5 (enExample)
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment